Actively Recruiting
Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)
Led by Sunkaky Medical Cooperation · Updated on 2025-07-17
20
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
Sponsors
S
Sunkaky Medical Cooperation
Lead Sponsor
W
Wish Fertility Hospital Pvt. Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to investigate the potential of autologous adipose stem cell (ASC) mitochondrial transfer (ASCENT) to oocytes along with intracytoplasmic sperm injection (ICSI)as a means of enhancing embryo development and improving the success rate of in patients with a history of multiple IVF failures. Embryo quality plays a crucial role in determining the success of assisted reproductive technologies and directly contributes to repeated pregnancy failures. Several factors, including age, physiological conditions, genetics, and environmental influences, can significantly impact embryo quality. Oocytes, the largest cells in the human body, are heavily reliant on mitochondria. Mitochondria's role in providing energy for oocytes is crucial, and insufficient energy production has been linked to poor oocyte and embryo quality. Some human studies have shown that increasing oocyte mitochondrial mass can improve embryo quality in patients who have experienced repeated IVF failures.
CONDITIONS
Official Title
Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Having at least three previous failed IVF trials
- Consent to collect biopsies for Preimplantation Genetic Testing for Aneuploidy (PGTA) analysis
- Consent to have single blastocyst transfer (recommended)
- No major uterine or ovarian abnormalities
- Consent to have all embryos frozen
- Consent to collect adipose tissue via subcutaneous liposuction
- Body mass index (BMI) less than 26 kg/m2
You will not qualify if you...
- Ovarian endometriosis with Chocolate cysts classified as American Fertility Society (AFS) type 3 or 4
- Medical contraindications to oocyte retrieval or related procedures
- Ovarian hyperstimulation syndrome
- Bleeding disorders
- Sex hormone allergies
- Severe emotional disorders affecting injections
- Severe sperm abnormalities
- Motile sperm count less than 5 million per mL
- Uterine structural anomalies
- Polycystic ovaries
- Premature ovarian failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wish Fertility Hospital Pvt. Ltd
Colombo, Sri Lanka
Actively Recruiting
Research Team
D
Dr. SANATHUDAYANGA KANKANAMGAMAGE, PhD
CONTACT
D
Dr. HELARUWAN PASAN KUMARA WA, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here